NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

The primary endpoint of NVCR's EF-11 trial was PFS. For the rGBM setting the FDA has been allowing that endpoint. It was clearly met so the trial was a success.

One can fairly argue that PFS w/o OS is questionable, but that is up to regulators to decide.

For nGBM, where NWBO is, the NVCR EF-14 trial was highly stat sig for OS between the trial arms despite crossover.